Norman E. Lepor, MD, FACC, FAHA, FSCAI
Known for his interest in graduate medical education and investigations in the field of interventional cardiology. Dr. Lepor is cofounder of Reviews in Cardiovascular Medicine. He is Clinical Professor of Medicine at The David Geffen School of Medicine at UCLA and an attending interventional cardiologist at Cedars-Sinai Heart Institute. He has directed investigations into the study of interventions in acute myocardial infarction, treatment and prevention of coronary artery disease, contrast nephropathy, oral antiplatelet and anticoagulant agents, atrial arrhythmias, and appropriate use of cardiovascular imaging. Dr. Lepor has lectured widely on such topics as the utility of advanced cardiovascular imaging technologies and the prevention and treatment of cardiovascular disease.
Peter A. McCollough, MD, MPH, FACC, FAHA, FACP, FCCP, FNKF
After receiving a bachelor's degree from Baylor University, Dr McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough directs cardiovascular education and research for the Baylor Health Care System and is a Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications. Dr. McCullough has won numerous awards including in the Simon Dack Award from the American College of Cardiology for outstanding scholarship and the International Vicenza Award for Critical Care Nephrology for his contributions and dedication to the emerging problem of cardiorenal syndromes.
Gregg C. Fonarow, MD, FACC, FAHA
An eminent specialist in heart failure management, preventive cardiology, quality of care, and outcomes research. Dr. Fonarow holds the Eliot Corday Chair in Cardiovascular Medicine and Science. He is a Professor of Medicine in the Division of Cardiology at The David Geffen School of Medicine at UCLA, Director of the Ahmanson-UCLA Cardiomyopathy Center, and Co-Chief of the UCLA Division of Cardiology.
Gregg W. Stone, MD, FACC, FSCAI
Dr. Stone is Professor of Medicine at Columbia University, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapies at Columbia University Medical Center, and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation in New York, NY. Dr. Stone has served as the lead principal investigator for more than 60 national and international multicenter randomized trials, and is the Co-Director of Transcatheter Cardiovascular Therapeutics, the world's largest symposium devoted to interventional cardiology and vascular medicine.
Norman E. Lepor, MD, FACC, FAHA, FSCAI
William T. Abraham, MD, FACP, FACC
Dr. Abraham is Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University in Columbus, OH. He earned his medical degree from Harvard University and completed postgraduate training at the University of Colorado. Dr. Abraham's clinical activities and research interests focus on heart failure. He has received grants from the National Institutes of Health and participated in more than 100 multicenter clinical drug and device trials. In addition to authoring more than 600 original works. Dr. Abraham has co-edited a leading textbook. Heart Failure: A Practical Approach to Treatment.
Christopher P. Cannon, MD, FACC
Dr. Cannon is a Professor of Medicine at Harvard Medical School, and a He is a senior investigator in the Thrombolysis In Myocardial Infarction (TIMI) Study Group in the Cardiovascular Division at Brigham and Women's Hospital in Boston. He has or is leading 14 international trials in the field of acute coronary syndromes and prevention. He is Editor-in-Chief of the journal Critical Pathways in Cardiology and Deputy Editor-in-Chief of Clinical Cardiology, as well as Editor-in-Chief of CardioSource Science and Quality, the American College of Cardiology's Web site (www.cardiosource.org).
Michael H. Davidson, MD, FACC, FACP
Dr. Davidson is Clinical Professor and Director of Preventive Cardiology at the University of Chicago. He also serves as Chief Medical Officer for Omthera Pharmaceuticals. Dr. Davidson's clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. Dr. Davidson has coordinated more than 1000 clinical trials in areas of preventive cardiology, published more than 250 articles for leading medical journals, and has written three books on lipidology.
Prakash C. Deedwania, MD, FACC, FAHA, FACP, FCCP
Dr. Deedwania is one of the most recognizable figures in the fields of hypertension, heart failure, lipid disorders, ischemic heart disease, rhythm disorders and preventive cardiology. He is Professor of Medicine at the University of California -San Francisco (UCSF) School of Medicine and is Chief of the Cardiology Division for the Veterans Administration Central California Health Care System. Dr. Deedwania is also Director of Cardiovascular Research for the UCSF Fresno -Central San Joaquin Valley Medical Education Program and Clinical Professor of Medicine at Stanford University in Palo Alto, CA. He has authored numerous landmark clinical trials and has authored or co-authored more than 350 publications.
Alice K. Jacobs, MD, FACC, FAHA
Dr. Jacobs is a Professor of Medicine at Boston University School of Medicine and the Director of Invasive Cardiology Services at Boston Medical Center. Her major research interest is in coronary revascularization strategies. Dr. Jacobs is the principal investigator of the MASS COMM trial, which is evaluating the safety and efficacy of coronary angioplasty performed in community hospitals without on-site cardiac surgery in Massachusetts. She is also interested in cardiovascular disease in women and the sex-based differences in the epidemiology, diagnosis, treatment and prognosis of ischemic heart disease.
Dean J. Kereiakes, MD, FACC, FSCAI
An active clinical and scientific investigator. Dr. Kereiakes is Medical Director of The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education; and Professor of Clinical Medicine at Ohio State University. Dr Kereiakes serves on the scientific advisory boards for multiple medical device companies and on the editorial boards of seven major cardiovascular journals. He maintains an active practice in interventional cardiology.
Mikhail Kosiborod, MD, FACC, FAHA
Dr. Kosiborod is a cardiologist and a clinical scholar at Saint Luke's Mid America Heart Institute, and Associate Professor of Medicine at the University of Missouri-Kansas City. His main research interests include diabetes and glucose management in patients with acute coronary syndromes. He has authored and co-authored many peer-reviewed publications and abstracts, including several scientific statements and position documents on in-hospital and long-term glucose control. Dr. Kosiborod is a recipient of several American Heart Association research awards. He is actively involved in the work of many committees for the American College of Cardiology and American Heart Association.
Gerald M. Pohost, MD, FACC, FAHA
Dr. Pohost is known worldwide for his contributions to cardiovascular imaging. His pioneering efforts led to the development of thallium for clinical myocardial imaging and the field of cardiovascular magnetic resonance imaging. His leadership led to the establishment of the (International) Society for Magnetic Resonance in Medicine and the Society for Cardiovascular Magnetic Resonance. He is a Professor at the Keck School of Medicine and the Viterbi School of Engineering at the University of Southern California, and a Professor at the Loma Linda University School of Medicine. Dr. Pohost has been working on developing and applying approaches for diagnostic image analysis in China and has received professorships at three universities in China.
Matthew J. Price, MD, FACC, FSCAI
Dr. Price is an interventional cardiologist and currently serves as Director of the Cardiac Catheterization Laboratory in the Cardiovascular Division of Scripps Clinic and Assistant Professor at the Scripps Translational Science Institute. Dr Price has published numerous papers and chapters on high-risk percutaneous coronary intervention (PCI), drug-eluting stents, and the impact of antiplatelet therapy on outcomes after stent implantation. He is involved in the leadership of several trials examining the safety and efficacy of antiplatelet therapy during and after PCI.
Prediman K. Shah, MD, FACC, FACP, FCCP
Dr. Shah is Director of the Division of Cardiology and Director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center in Los Angeles, where he holds the Shapell and Webb Family Chair in Clinical Cardiology at Cedars-Sinai. He is also Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Shah is currently leading several studies that focus on heart disease prevention and treatment. In March, 2012, Dr. Shah received the Distinguished Scientific Achievement award (basic science category) from the American College of Cardiology. He has edited three books on heart disease and published more than 600 scientific papers, reviews, book chapters and abstracts.
Karol E. Watson, MD, PHD, FACC
Dr. Watson is a full-time cardiologist at The David Geffen School of Medicine at UCLA. Currently, Dr. Watson is director of the Women's Cardiovascular Center at UCLA, Co-Director of the UCLA Program in Preventative Cardiology, and director for the Center for Cholesterol and Hypertension Management. A Principal Investigator for several large National Institutes of Health studies. Dr. Watson's more than 80 publications and presentations have addressed many subjects including prevention of heart disease, vascular calcification, hormone replacement therapy, the metabolic syndrome, hypertension, hypercholesterolemia, and cardiovascular disease in women and African Americans.
Norman E. Lepor, MD, FACC, FAHA, FSCAI
Known for his interest in graduate medical education and investigations in the field of interventional cardiology. Dr. Lepor is cofounder of Reviews in Cardiovascular Medicine. He is Clinical Professor of Medicine at The David Geffen School of Medicine at UCLA and an attending interventional cardiologist at Cedars-Sinai Heart Institute. He has directed investigations into the study of interventions in acute myocardial infarction, treatment and prevention of coronary artery disease, contrast nephropathy, oral antiplatelet and anticoagulant agents, atrial arrhythmias, and appropriate use of cardiovascular imaging. Dr. Lepor has lectured widely on such topics as the utility of advanced cardiovascular imaging technologies and the prevention and treatment of cardiovascular disease.
Peter A. McCollough, MD, MPH, FACC, FAHA, FACP, FCCP, FNKF
After receiving a bachelor's degree from Baylor University, Dr McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough directs cardiovascular education and research for the Baylor Health Care System and is a Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications. Dr. McCullough has won numerous awards including in the Simon Dack Award from the American College of Cardiology for outstanding scholarship and the International Vicenza Award for Critical Care Nephrology for his contributions and dedication to the emerging problem of cardiorenal syndromes.
Gregg C. Fonarow, MD, FACC, FAHA
An eminent specialist in heart failure management, preventive cardiology, quality of care, and outcomes research. Dr. Fonarow holds the Eliot Corday Chair in Cardiovascular Medicine and Science. He is a Professor of Medicine in the Division of Cardiology at The David Geffen School of Medicine at UCLA, Director of the Ahmanson-UCLA Cardiomyopathy Center, and Co-Chief of the UCLA Division of Cardiology.
Gregg W. Stone, MD, FACC, FSCAI
Dr. Stone is Professor of Medicine at Columbia University, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapies at Columbia University Medical Center, and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation in New York, NY. Dr. Stone has served as the lead principal investigator for more than 60 national and international multicenter randomized trials, and is the Co-Director of Transcatheter Cardiovascular Therapeutics, the world's largest symposium devoted to interventional cardiology and vascular medicine.
John B. Gordon, MD, FACC
John Gordon is in private practice and a partner at the San Diego Cardiac Center Medical Group, which he joined in 1989. He is a senior interventional cardiologist at Sharp Memorial Hospital where he launched the peripheral interventions program in the Cardiac Catheterization Laboratory, and the Sharp Memorial STEMI program. He has served as Chief of the Cardiology Subsection and Vice Chair of the Internal Medicine Supervisory Committee at Sharp Memorial Hospital. He has served as President of the American Heart Association, San Diego Chapter.
Dr. Gordon's current research interests include coronary and peripheral interventions, and the late sequelae of Kawasaki Disease in adults. He is Director of the Annual Maui Cardiovascular Symposium, now in its tenth year, which is sponsored by the CA ACC.
William T. Abraham, MD, FACP, FACC
Dr. Abraham is Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University in Columbus, OH. He earned his medical degree from Harvard University and completed postgraduate training at the University of Colorado. Dr. Abraham's clinical activities and research interests focus on heart failure. He has received grants from the National Institutes of Health and participated in more than 100 multicenter clinical drug and device trials. In addition to authoring more than 600 original works. Dr. Abraham has co-edited a leading textbook. Heart Failure: A Practical Approach to Treatment.
Christopher P. Cannon, MD, FACC
Dr. Cannon is a Professor of Medicine at Harvard Medical School, and a He is a senior investigator in the Thrombolysis In Myocardial Infarction (TIMI) Study Group in the Cardiovascular Division at Brigham and Women's Hospital in Boston. He has or is leading 14 international trials in the field of acute coronary syndromes and prevention. He is Editor-in-Chief of the journal Critical Pathways in Cardiology and Deputy Editor-in-Chief of Clinical Cardiology, as well as Editor-in-Chief of CardioSource Science and Quality, the American College of Cardiology's Web site (www.cardiosource.org).
Michael H. Davidson, MD, FACC, FACP
Dr. Davidson is Clinical Professor and Director of Preventive Cardiology at the University of Chicago. He also serves as Chief Medical Officer for Omthera Pharmaceuticals. Dr. Davidson's clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. Dr. Davidson has coordinated more than 1000 clinical trials in areas of preventive cardiology, published more than 250 articles for leading medical journals, and has written three books on lipidology.
Prakash C. Deedwania, MD, FACC, FAHA, FACP, FCCP
Dr. Deedwania is one of the most recognizable figures in the fields of hypertension, heart failure, lipid disorders, ischemic heart disease, rhythm disorders and preventive cardiology. He is Professor of Medicine at the University of California -San Francisco (UCSF) School of Medicine and is Chief of the Cardiology Division for the Veterans Administration Central California Health Care System. Dr. Deedwania is also Director of Cardiovascular Research for the UCSF Fresno -Central San Joaquin Valley Medical Education Program and Clinical Professor of Medicine at Stanford University in Palo Alto, CA. He has authored numerous landmark clinical trials and has authored or co-authored more than 350 publications.
Alice K. Jacobs, MD, FACC, FAHA
Dr. Jacobs is a Professor of Medicine at Boston University School of Medicine and the Director of Invasive Cardiology Services at Boston Medical Center. Her major research interest is in coronary revascularization strategies. Dr. Jacobs is the principal investigator of the MASS COMM trial, which is evaluating the safety and efficacy of coronary angioplasty performed in community hospitals without on-site cardiac surgery in Massachusetts. She is also interested in cardiovascular disease in women and the sex-based differences in the epidemiology, diagnosis, treatment and prognosis of ischemic heart disease.
Dean J. Kereiakes, MD, FACC, FSCAI
An active clinical and scientific investigator. Dr. Kereiakes is Medical Director of The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education; and Professor of Clinical Medicine at Ohio State University. Dr Kereiakes serves on the scientific advisory boards for multiple medical device companies and on the editorial boards of seven major cardiovascular journals. He maintains an active practice in interventional cardiology.
Mikhail Kosiborod, MD, FACC, FAHA
Dr. Kosiborod is a cardiologist and a clinical scholar at Saint Luke's Mid America Heart Institute, and Associate Professor of Medicine at the University of Missouri-Kansas City. His main research interests include diabetes and glucose management in patients with acute coronary syndromes. He has authored and co-authored many peer-reviewed publications and abstracts, including several scientific statements and position documents on in-hospital and long-term glucose control. Dr. Kosiborod is a recipient of several American Heart Association research awards. He is actively involved in the work of many committees for the American College of Cardiology and American Heart Association.
Gerald M. Pohost, MD, FACC, FAHA
Dr. Pohost is known worldwide for his contributions to cardiovascular imaging. His pioneering efforts led to the development of thallium for clinical myocardial imaging and the field of cardiovascular magnetic resonance imaging. His leadership led to the establishment of the (International) Society for Magnetic Resonance in Medicine and the Society for Cardiovascular Magnetic Resonance. He is a Professor at the Keck School of Medicine and the Viterbi School of Engineering at the University of Southern California, and a Professor at the Loma Linda University School of Medicine. Dr. Pohost has been working on developing and applying approaches for diagnostic image analysis in China and has received professorships at three universities in China.
Matthew J. Price, MD, FACC, FSCAI
Dr. Price is an interventional cardiologist and currently serves as Director of the Cardiac Catheterization Laboratory in the Cardiovascular Division of Scripps Clinic and Assistant Professor at the Scripps Translational Science Institute. Dr Price has published numerous papers and chapters on high-risk percutaneous coronary intervention (PCI), drug-eluting stents, and the impact of antiplatelet therapy on outcomes after stent implantation. He is involved in the leadership of several trials examining the safety and efficacy of antiplatelet therapy during and after PCI.
Prediman K. Shah, MD, FACC, FACP, FCCP
Dr. Shah is Director of the Division of Cardiology and Director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center in Los Angeles, where he holds the Shapell and Webb Family Chair in Clinical Cardiology at Cedars-Sinai. He is also Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Shah is currently leading several studies that focus on heart disease prevention and treatment. In March, 2012, Dr. Shah received the Distinguished Scientific Achievement award (basic science category) from the American College of Cardiology. He has edited three books on heart disease and published more than 600 scientific papers, reviews, book chapters and abstracts.
Karol E. Watson, MD, PHD, FACC
Dr. Watson is a full-time cardiologist at The David Geffen School of Medicine at UCLA. Currently, Dr. Watson is director of the Women's Cardiovascular Center at UCLA, Co-Director of the UCLA Program in Preventative Cardiology, and director for the Center for Cholesterol and Hypertension Management. A Principal Investigator for several large National Institutes of Health studies. Dr. Watson's more than 80 publications and presentations have addressed many subjects including prevention of heart disease, vascular calcification, hormone replacement therapy, the metabolic syndrome, hypertension, hypercholesterolemia, and cardiovascular disease in women and African Americans.
Norman E. Lepor, MD, FACC, FAHA, FSCAI
Known for his interest in graduate medical education and investigations in the field of interventional cardiology. Dr. Lepor is cofounder of Reviews in Cardiovascular Medicine. He is Clinical Professor of Medicine at The David Geffen School of Medicine at UCLA and an attending interventional cardiologist at Cedars-Sinai Heart Institute. He has directed investigations into the study of interventions in acute myocardial infarction, treatment and prevention of coronary artery disease, contrast nephropathy, oral antiplatelet and anticoagulant agents, atrial arrhythmias, and appropriate use of cardiovascular imaging. Dr. Lepor has lectured widely on such topics as the utility of advanced cardiovascular imaging technologies and the prevention and treatment of cardiovascular disease.
Peter A. McCollough, MD, MPH, FACC, FAHA, FACP, FCCP, FNKF
After receiving a bachelor's degree from Baylor University, Dr McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough directs cardiovascular education and research for the Baylor Health Care System and is a Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications. Dr. McCullough has won numerous awards including in the Simon Dack Award from the American College of Cardiology for outstanding scholarship and the International Vicenza Award for Critical Care Nephrology for his contributions and dedication to the emerging problem of cardiorenal syndromes.
Gregg C. Fonarow, MD, FACC, FAHA
An eminent specialist in heart failure management, preventive cardiology, quality of care, and outcomes research. Dr. Fonarow holds the Eliot Corday Chair in Cardiovascular Medicine and Science. He is a Professor of Medicine in the Division of Cardiology at The David Geffen School of Medicine at UCLA, Director of the Ahmanson-UCLA Cardiomyopathy Center, and Co-Chief of the UCLA Division of Cardiology.
Gregg W. Stone, MD, FACC, FSCAI
Dr. Stone is Professor of Medicine at Columbia University, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapies at Columbia University Medical Center, and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation in New York, NY. Dr. Stone has served as the lead principal investigator for more than 60 national and international multicenter randomized trials, and is the Co-Director of Transcatheter Cardiovascular Therapeutics, the world's largest symposium devoted to interventional cardiology and vascular medicine.
John B. Gordon, MD, FACC
John Gordon is in private practice and a partner at the San Diego Cardiac Center Medical Group, which he joined in 1989. He is a senior interventional cardiologist at Sharp Memorial Hospital where he launched the peripheral interventions program in the Cardiac Catheterization Laboratory, and the Sharp Memorial STEMI program. He has served as Chief of the Cardiology Subsection and Vice Chair of the Internal Medicine Supervisory Committee at Sharp Memorial Hospital. He has served as President of the American Heart Association, San Diego Chapter.
Dr. Gordon's current research interests include coronary and peripheral interventions, and the late sequelae of Kawasaki Disease in adults. He is Director of the Annual Maui Cardiovascular Symposium, now in its tenth year, which is sponsored by the CA ACC.
William T. Abraham, MD, FACP, FACC
Dr. Abraham is Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University in Columbus, OH. He earned his medical degree from Harvard University and completed postgraduate training at the University of Colorado. Dr. Abraham's clinical activities and research interests focus on heart failure. He has received grants from the National Institutes of Health and participated in more than 100 multicenter clinical drug and device trials. In addition to authoring more than 600 original works. Dr. Abraham has co-edited a leading textbook. Heart Failure: A Practical Approach to Treatment.
Christopher P. Cannon, MD, FACC
Dr. Cannon is a Professor of Medicine at Harvard Medical School, and a He is a senior investigator in the Thrombolysis In Myocardial Infarction (TIMI) Study Group in the Cardiovascular Division at Brigham and Women's Hospital in Boston. He has or is leading 14 international trials in the field of acute coronary syndromes and prevention. He is Editor-in-Chief of the journal Critical Pathways in Cardiology and Deputy Editor-in-Chief of Clinical Cardiology, as well as Editor-in-Chief of CardioSource Science and Quality, the American College of Cardiology's Web site (www.cardiosource.org).
Michael H. Davidson, MD, FACC, FACP
Dr. Davidson is Clinical Professor and Director of Preventive Cardiology at the University of Chicago. He also serves as Chief Medical Officer for Omthera Pharmaceuticals. Dr. Davidson's clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. Dr. Davidson has coordinated more than 1000 clinical trials in areas of preventive cardiology, published more than 250 articles for leading medical journals, and has written three books on lipidology.
Prakash C. Deedwania, MD, FACC, FAHA, FACP, FCCP
Dr. Deedwania is one of the most recognizable figures in the fields of hypertension, heart failure, lipid disorders, ischemic heart disease, rhythm disorders and preventive cardiology. He is Professor of Medicine at the University of California -San Francisco (UCSF) School of Medicine and is Chief of the Cardiology Division for the Veterans Administration Central California Health Care System. Dr. Deedwania is also Director of Cardiovascular Research for the UCSF Fresno -Central San Joaquin Valley Medical Education Program and Clinical Professor of Medicine at Stanford University in Palo Alto, CA. He has authored numerous landmark clinical trials and has authored or co-authored more than 350 publications.
Alice K. Jacobs, MD, FACC, FAHA
Dr. Jacobs is a Professor of Medicine at Boston University School of Medicine and the Director of Invasive Cardiology Services at Boston Medical Center. Her major research interest is in coronary revascularization strategies. Dr. Jacobs is the principal investigator of the MASS COMM trial, which is evaluating the safety and efficacy of coronary angioplasty performed in community hospitals without on-site cardiac surgery in Massachusetts. She is also interested in cardiovascular disease in women and the sex-based differences in the epidemiology, diagnosis, treatment and prognosis of ischemic heart disease.
Dean J. Kereiakes, MD, FACC, FSCAI
An active clinical and scientific investigator. Dr. Kereiakes is Medical Director of The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education; and Professor of Clinical Medicine at Ohio State University. Dr Kereiakes serves on the scientific advisory boards for multiple medical device companies and on the editorial boards of seven major cardiovascular journals. He maintains an active practice in interventional cardiology.
Mikhail Kosiborod, MD, FACC, FAHA
Dr. Kosiborod is a cardiologist and a clinical scholar at Saint Luke's Mid America Heart Institute, and Associate Professor of Medicine at the University of Missouri-Kansas City. His main research interests include diabetes and glucose management in patients with acute coronary syndromes. He has authored and co-authored many peer-reviewed publications and abstracts, including several scientific statements and position documents on in-hospital and long-term glucose control. Dr. Kosiborod is a recipient of several American Heart Association research awards. He is actively involved in the work of many committees for the American College of Cardiology and American Heart Association.
Gerald M. Pohost, MD, FACC, FAHA
Dr. Pohost is known worldwide for his contributions to cardiovascular imaging. His pioneering efforts led to the development of thallium for clinical myocardial imaging and the field of cardiovascular magnetic resonance imaging. His leadership led to the establishment of the (International) Society for Magnetic Resonance in Medicine and the Society for Cardiovascular Magnetic Resonance. He is a Professor at the Keck School of Medicine and the Viterbi School of Engineering at the University of Southern California, and a Professor at the Loma Linda University School of Medicine. Dr. Pohost has been working on developing and applying approaches for diagnostic image analysis in China and has received professorships at three universities in China.
Matthew J. Price, MD, FACC, FSCAI
Dr. Price is an interventional cardiologist and currently serves as Director of the Cardiac Catheterization Laboratory in the Cardiovascular Division of Scripps Clinic and Assistant Professor at the Scripps Translational Science Institute. Dr Price has published numerous papers and chapters on high-risk percutaneous coronary intervention (PCI), drug-eluting stents, and the impact of antiplatelet therapy on outcomes after stent implantation. He is involved in the leadership of several trials examining the safety and efficacy of antiplatelet therapy during and after PCI.
Prediman K. Shah, MD, FACC, FACP, FCCP
Dr. Shah is Director of the Division of Cardiology and Director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center in Los Angeles, where he holds the Shapell and Webb Family Chair in Clinical Cardiology at Cedars-Sinai. He is also Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Shah is currently leading several studies that focus on heart disease prevention and treatment. In March, 2012, Dr. Shah received the Distinguished Scientific Achievement award (basic science category) from the American College of Cardiology. He has edited three books on heart disease and published more than 600 scientific papers, reviews, book chapters and abstracts.
Karol E. Watson, MD, PHD, FACC
Dr. Watson is a full-time cardiologist at The David Geffen School of Medicine at UCLA. Currently, Dr. Watson is director of the Women's Cardiovascular Center at UCLA, Co-Director of the UCLA Program in Preventative Cardiology, and director for the Center for Cholesterol and Hypertension Management. A Principal Investigator for several large National Institutes of Health studies. Dr. Watson's more than 80 publications and presentations have addressed many subjects including prevention of heart disease, vascular calcification, hormone replacement therapy, the metabolic syndrome, hypertension, hypercholesterolemia, and cardiovascular disease in women and African Americans.